Baker Biotech Capital (GP), LLC Insider Trading $ALTH ALLOS THERAPEUTICS INC
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Baker Biotech Capital (GP), LLC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Baker Biotech Capital (GP), LLC. Baker Biotech Capital (GP), LLC is 10% Owner in BIOCRYST PHARMACEUTICALS INC ($BCRX) and Director in INCYTE CORP ($INCY) and Director in NEUROGEN CORP ($NRGN) and 10% Owner in IDERA PHARMACEUTICALS, INC. ($IDRA) and 10% Owner in PHARMACYCLICS INC ($PCYC) and 10% Owner in VIROPHARMA INC ($VPHM) and 10% Owner in ADOLOR CORP ($ADLR) and 10% Owner in ALLOS THERAPEUTICS INC ($ALTH) and 10% Owner in Ardea Biosciences, Inc./DE ($IBPI) and Director in SEATTLE GENETICS INC /WA ($SGEN) and Director in GENOMIC HEALTH INC ($GHDX) and 10% Owner in AUXILIUM PHARMACEUTICALS INC ($AUXL).
Baker Biotech Capital (GP), LLC in ALLOS THERAPEUTICS INC
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Baker Biotech Capital (GP), LLC: 10% Owner
Holdings: 2,022,293 shares
Latest Transaction: Feb 06 2009
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of Baker Biotech Capital (GP), LLC in ALLOS THERAPEUTICS INC
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ADLR, ALTH, IBPI, AUXL, BCRX, GHDX, IDRA, INCY, NRGN, PCYC, SGEN, VPHM
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 06 2009 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 8.26 | 235 | 1,940 | 2,022,293 | 2 M to 2 M (-0.01 %) |
| Feb 06 2009 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 8.17 | 263,312 | 2,152,260 | 2,022,528 | 2.3 M to 2 M (-11.52 %) |
| Feb 06 2009 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 8.11 | 50,041 | 405,617 | 2,285,840 | 2.3 M to 2.3 M (-2.14 %) |
| Feb 06 2009 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 8.17 | 12,713 | 103,882 | 2,335,881 | 2.3 M to 2.3 M (-0.54 %) |
| Feb 06 2009 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 8.16 | 67,709 | 552,729 | 2,348,594 | 2.4 M to 2.3 M (-2.80 %) |
| Feb 06 2009 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 8.46 | 256,936 | 2,173,524 | 2,416,303 | 2.7 M to 2.4 M (-9.61 %) |
| Feb 06 2009 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 8.47 | 27,485 | 232,781 | 2,373,239 | 2.4 M to 2.4 M (-1.14 %) |
| Feb 06 2009 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 9.03 | 2,859 | 25,823 | 2,700,724 | 2.7 M to 2.7 M (-0.11 %) |
| Feb 06 2009 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 8.01 | 100,309 | 803,104 | 2,703,583 | 2.8 M to 2.7 M (-3.58 %) |
| May 27 2008 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 5.64 | 316,754 | 1,786,493 | 2,803,892 | 2.5 M to 2.8 M (+12.74 %) |
| Feb 27 2008 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 6.00 | 11,730 | 70,380 | 2,487,138 | 2.5 M to 2.5 M (+0.47 %) |
| Feb 21 2008 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 6.20 | 8,211 | 50,908 | 2,475,408 | 2.5 M to 2.5 M (+0.33 %) |
| Feb 21 2008 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 5.90 | 8,797 | 51,902 | 2,467,197 | 2.5 M to 2.5 M (+0.36 %) |
| Feb 21 2008 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 6.50 | 8,940 | 58,105 | 2,458,400 | 2.4 M to 2.5 M (+0.36 %) |
| Feb 21 2008 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 6.75 | 8,862 | 59,850 | 2,449,460 | 2.4 M to 2.4 M (+0.36 %) |
| Jan 23 2008 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 6.92 | 161 | 1,113 | 2,440,598 | 2.4 M to 2.4 M (+0.01 %) |
| Jan 23 2008 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 7.15 | 1,246 | 8,913 | 2,440,437 | 2.4 M to 2.4 M (+0.05 %) |
| Jan 23 2008 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 7.22 | 1,430 | 10,318 | 2,439,191 | 2.4 M to 2.4 M (+0.06 %) |
| Jan 17 2008 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 7.50 | 5,600 | 42,000 | 2,437,761 | 2.4 M to 2.4 M (+0.23 %) |
| Jan 14 2008 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 7.41 | 35,405 | 262,521 | 2,432,161 | 2.4 M to 2.4 M (+1.48 %) |
| Jan 14 2008 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 7.47 | 14,979 | 111,940 | 2,396,756 | 2.4 M to 2.4 M (+0.63 %) |
| Jan 14 2008 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 7.47 | 31,538 | 235,564 | 2,381,777 | 2.4 M to 2.4 M (+1.34 %) |
| Jan 09 2008 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 6.96 | 16,994 | 118,282 | 2,350,239 | 2.3 M to 2.4 M (+0.73 %) |
| Jan 09 2008 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 7.21 | 54,470 | 392,821 | 2,333,245 | 2.3 M to 2.3 M (+2.39 %) |
| Jan 09 2008 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 6.85 | 27,235 | 186,560 | 2,278,775 | 2.3 M to 2.3 M (+1.21 %) |
| Jan 09 2008 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 6.37 | 338 | 2,153 | 2,251,540 | 2.3 M to 2.3 M (+0.02 %) |
| Jan 09 2008 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 6.37 | 55 | 350 | 2,251,202 | 2.3 M to 2.3 M (0.00 %) |
| Jun 21 2007 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 5.55 | 23,100 | 128,235 | 2,251,147 | 2.3 M to 2.3 M (-1.02 %) |
| Jun 21 2007 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 5.85 | 45,968 | 268,798 | 2,274,247 | 2.3 M to 2.3 M (-1.98 %) |
| Jun 21 2007 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 5.64 | 194,879 | 1,098,747 | 2,320,215 | 2.5 M to 2.3 M (-7.75 %) |
| Jun 21 2007 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 5.76 | 41,996 | 241,742 | 2,515,094 | 2.6 M to 2.5 M (-1.64 %) |
| Feb 01 2007 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 6.00 | 838,296 | 5,029,776 | 2,557,090 | 1.7 M to 2.6 M (+48.77 %) |
| Nov 30 2006 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 5.50 | 77,313 | 425,222 | 1,718,794 | 1.6 M to 1.7 M (+4.71 %) |
| Nov 20 2006 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 5.75 | 30,175 | 173,392 | 1,641,481 | 1.6 M to 1.6 M (+1.87 %) |
| Nov 20 2006 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 5.80 | 40,671 | 236,010 | 1,611,306 | 1.6 M to 1.6 M (+2.59 %) |
| Nov 20 2006 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 5.66 | 120,702 | 682,811 | 1,570,635 | 1.4 M to 1.6 M (+8.32 %) |
Page: 1